1,721,417 research outputs found
Supplementary_data – Supplemental material for MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A
No full textSupplemental material, Supplementary_data for MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A by Xiang-Yun Ye, Ling Xu, Shun Lu and Zhi-Wei Chen in International Journal of Immunopathology and Pharmacology</p
Figure_S1 – Supplemental material for MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A
No full textSupplemental material, Figure_S1 for MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A by Xiang-Yun Ye, Ling Xu, Shun Lu and Zhi-Wei Chen in International Journal of Immunopathology and Pharmacology</p
Figure_S2 – Supplemental material for MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A
No full textSupplemental material, Figure_S2 for MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A by Xiang-Yun Ye, Ling Xu, Shun Lu and Zhi-Wei Chen in International Journal of Immunopathology and Pharmacology</p
sj-jpg-4-tam-10.1177_17588359231156387 – Supplemental material for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
No full textSupplemental material, sj-jpg-4-tam-10.1177_17588359231156387 for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li and Shun Lu in Therapeutic Advances in Medical Oncology</p
sj-jpg-6-tam-10.1177_17588359231156387 – Supplemental material for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
No full textSupplemental material, sj-jpg-6-tam-10.1177_17588359231156387 for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li and Shun Lu in Therapeutic Advances in Medical Oncology</p
sj-jpg-3-tam-10.1177_17588359231156387 – Supplemental material for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
No full textSupplemental material, sj-jpg-3-tam-10.1177_17588359231156387 for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li and Shun Lu in Therapeutic Advances in Medical Oncology</p
sj-jpg-2-tam-10.1177_17588359231156387 – Supplemental material for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
No full textSupplemental material, sj-jpg-2-tam-10.1177_17588359231156387 for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li and Shun Lu in Therapeutic Advances in Medical Oncology</p
sj-jpg-5-tam-10.1177_17588359231156387 – Supplemental material for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
No full textSupplemental material, sj-jpg-5-tam-10.1177_17588359231156387 for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li and Shun Lu in Therapeutic Advances in Medical Oncology</p
sj-jpg-7-tam-10.1177_17588359231156387 – Supplemental material for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
No full textSupplemental material, sj-jpg-7-tam-10.1177_17588359231156387 for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li and Shun Lu in Therapeutic Advances in Medical Oncology</p
sj-jpg-1-tam-10.1177_17588359231156387 – Supplemental material for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
No full textSupplemental material, sj-jpg-1-tam-10.1177_17588359231156387 for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li and Shun Lu in Therapeutic Advances in Medical Oncology</p
- …
